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9ABBREVIATIONS
AA = amino acid
AGE = advanced glycation end products
APD = automated peritoneal dialysis
BMI = body mass index
CA125 = cancer antigen 125
CAPD = continuous ambulatory peritoneal dialysis
Crea = creatinine
CRP = C-reactive protein
CV = coefficient of variation
EE = energy expenditure
EIA = enzyme immunoassay
ELISA = enzyme-linked immunosorbent assay
ESRD = end-stage renal disease
FFA = free fatty acids
GDP = glucose degradation products
GOX = glucose oxidation
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LDL = low density lipoprotein
LOX = lipid oxidation
LT = leukotriene
MCP-1 = monocyte chemoattractant protein-1
NS = not significant
PIIINP = procollagen III N-terminal peptide
PD = peritoneal dialysis
PDC test = Personal Dialysis Capacity Test
PET = Peritoneal Equilibration Test
PG = prostaglandin
QUICKI = Quantitative Insulin Sensitivity Check Index
RIA = radioimmunoassay
RQ = respiratory quotient
RQn = non-protein respiratory quotient
RRF = residual renal function
RRT = renal replacement therapy
SD = standard deviation
SEM = standard error of the mean
sIL-6R = soluble interleukin-6 receptor
SLE = systemic lupus erythematosus
sICAM-1 = soluble intercellular adhesion molecule-1
TGF-β = transforming growth factor-beta
TNF-α = tumour necrosis factor-alpha
TXB2 = thromboxane B2
USRDS = United States Renal Data System
VLDL = very low density lipoprotein
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ABSTRACT
Although peritoneal dialysis (PD) has proven
its utility in renal replacement therapy
(RRT), there are still several unsolved prob-
lems which reduce the greater acceptance
of PD. Peritonitis remains the major com-
plication of PD. Changes in peritoneal mem-
brane structure and function limit the long-
term use of PD. Furthermore, glucose ab-
sorbed from the dialysis solutions may ag-
gravate the metabolic disturbances found
in PD patients.
Aims:
One aim of the present study was to evalu-
ate whether dialysis adequacy and charac-
teristics of the peritoneal membrane corre-
late with the soluble factors measured from
the dialysate, and whether they change dur-
ing a one-year follow-up. Further, the ef-
fect of peritonitis on inflammatory param-
eters was studied in order to find out fac-
tors predicting the outcome of peritonitis.
The second aim was to evaluate whether
reducing the glucose load by replacing glu-
cose with icodextrin or amino acids as os-
motic agents is beneficial to metabolism and
host defence.
Methods:
The Personal Dialysis Capacity (PDC) test
and measurements of soluble factors (In-
terleukin-6 (IL-6), hyaluronan (HA), solu-
ble intercellular adhesion molecule-1 (sI-
CAM-1)) were performed three times dur-
ing one year to reveal changes in dialysis
adequacy, characteristics of the peritoneal
membrane, and changes in inflammatory
and fibrotic parameters in the dialysate, and
their correlation with each other.
Inflammatory parameters from serum
(C-reactive protein (CRP)) and the dialysate
(leukocytes, IL-6, HA, sICAM-1) were
measured during an acute episode of peri-
tonitis, and analysed in patients with differ-
ent outcomes. Further, the soluble factors
in the dialysate were measured two months
after the onset of peritonitis.
Metabolic analyses (serum lipids, short
insulin tolerance test for measuring insulin
sensitivity, and indirect calorimetry for
measuring substrate oxidation) were per-
formed after eight weeks of using one ex-
change of dialysis solution containing ami-
no acids (AA) or icodextrin (ID) and com-
pared to measurements during the use of
solely glucose-based solutions. Further,
cancer antigen 125 (CA125) and markers
of peritoneal host defence and inflamma-
tion (IL-6, HA, tumour necrosis factor-α
(TNF-α), sICAM-1) were analysed during
the use of glucose-free solutions and com-
pared to measurements during the use of
solely glucose-based solutions.
Results:
Concentrations of IL-6 were higher in the
dialysate than in serum. Plasma loss corre-
lated to area parameter and to inflammato-
ry factors in the dialysate. IL-6 in the dia-
lysate was higher in patients who had pre-
viously had peritonitis, and correlated to the
number of previous episodes of peritonitis.
There were no significant changes in dialy-
sis adequacy or membrane characteristics
during a one-year follow-up. The appear-
ance rate of IL-6 in the dialysate rose sig-
nificantly (419.8±63.3 vs. 784.1±136.4 vs.
1149.3±252.2 ng/24h, P=0.006), whereas
no significant changes in HA or sICAM-1
were seen.
During an acute episode of peritonitis,
all soluble factors had the highest concen-
trations at the onset and on day four of peri-
tonitis. Good outcome (n=28) was defined
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as disappearance of symptoms and signs
of peritonitis during the treatment with an-
tibiotics, whereas poor outcome (n=8)
meant transfer to haemodialysis or death
before completing the treatment of perito-
nitis. Four days after the onset of peritoni-
tis, CRP and dialysate leukocytes were sig-
nificantly higher in patients with poor out-
come. However, the soluble factors did not
differ in patients with good and poor out-
come during the first days of peritonitis. At
the end of the treatment with antibiotics,
sICAM-1 and HA were lower in the patients
with a later relapse/re-infection. Further, IL-
6 was higher two months after the onset of
peritonitis than in patients with no history
of peritonitis.
There were no changes in insulin sensi-
tivity during the use of either glucose-free
dialysis solution. Serum cholesterol
(4.8±0.3–4.5±0.3 mmol/L, P=0.045) and
free fatty acids ( 496.1±34.5–425.8±36.8
µmol/L, P=0.022) decreased during the use
of AA. Serum triglycerides declined during
the use of both ID (2.2±0.2–1.9±0.1 mmol/
L, P=0.019) and AA (1.9±0.2–1.6±0.1
mmol/L, P=0.024). Glucose oxidation de-
creased and lipid oxidation increased dur-
ing the use of ID, whereas no significant
changes were seen during the use of AA.
Energy expenditure values did not change
during the use of either study solution.
sICAM-1 and HA did not change signif-
icantly during the use of either glucose-free
dialysis solution. CA125 and IL-6 increased
during the use of AA. CRP in serum and
TNF-α and IL-6 in the dialysate increased
during the use of ID.
In conclusion, higher concentrations of
IL-6 in the dialysate than in serum support
local production of the soluble factors in
the peritoneum. Increasing IL-6 during a
one-year follow-up may reflect inflamma-
tory processes in the peritoneal membrane,
which may lead to alterations in peritoneal
function in the long run.
High CRP and high dialysate leukocytes
four days after the onset of peritonitis pre-
dicted poor outcome. Low sICAM-1 and
HA at the end of the treatment with antibi-
otics predicted a relapse/re-infection, and
may thus be a sign of reduced immune de-
fence of the peritoneum. High late concen-
trations of IL-6 in dialysate may reflect si-
lent inflammation in the peritoneal mem-
brane despite clinical recovery from peri-
tonitis.
Replacement of glucose with amino ac-
ids or icodextrin in one daily exchange had
a positive effect on serum lipids and sub-
strate oxidation. Increasing CA125 during
the use of AA indicates better preservation
of the mesothelium. Increasing inflamma-
tory parameters during the use of ID and
to a lesser extent during AA may be a sign
of enhanced host defence. However, in-
flammatory processes which may lead to
alterations in peritoneal function in the long
run, cannot totally be excluded.
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INTRODUCTION
Already in 1923 Professor Ganter per-
formed the first experimental peritoneal di-
alysis (PD) treatments in Germany (Ganter
1923, Teschner et al. 2004). He was con-
vinced of the superiority of his method over
the troublesome haemodialysis therapy, and
recommended its broader clinical applica-
tion (Ganter 1923, Teschner et al. 2004).
However, when Professor Ganter died in
1940, only 13 patients world-wide had been
treated with PD (Teschner et al. 2004). In
Finland Professor Kuhlbäck and his col-
leagues treated the first patients with PD in
1956 (Kuhlbäck and Kauste 1961). Contin-
uous ambulatory peritoneal dialysis (CAPD)
was introduced in the mid-1970s by Mon-
crief, Popovich and colleagues in the USA
(Popovich et al. 1978) and in 1979 by Dr.
Lampainen in Finland (Pasternack et al.
1981, Kuhlbäck 2002). At the end of 2003,
21% (301/1410) of all Finnish dialysis pa-
tients were treated with PD (Finnish Reg-
istry for Kidney Diseases, Annual Report
2003).
In the past few decades, major improve-
ments in solution delivery systems and di-
alysis solutions have enabled PD to become
a successful treatment modality of end-
stage renal diseases (ESRD). However, peri-
tonitis remains the major cause of acute
drop-out from PD, resulting in considera-
ble morbidity and transfer to haemodialysis
(Piraino et. al 2005). Severe or recurrent
episodes of peritonitis and bioincompatible
factors of the dialysis solutions may lead to
long-term changes in peritoneal function,
leading to loss of ultrafiltration and inade-
quate solute clearance (Davies et al. 1996,
Davies et al. 2001, De Vriese et al. 2001a).
One purpose of this study was to examine
whether soluble factors measured in the
dialysate are associated with peritoneal func-
tion, and how they change during one year
of follow-up. Furthermore, the course of
different systemic and local markers of in-
flammation during peritonitis and their role
as predictors of the outcome of peritonitis
were studied.
Mortality due to cardiovascular diseas-
es is high among PD patients (Finnish Reg-
istry for Kidney Diseases, Annual Report
2000). The patients often have several clas-
sical risk factors for cardiovascular diseas-
es, such as obesity, unfavourable lipid pro-
files, hyperglycaemia, hyperinsulinaemia
and signs of insulin resistance (DeFronzo
et al. 1981, Lindholm and Norbeck 1986,
Chen et al. 2001). It is known that part of
the glucose used as an osmotic agent in di-
alysis solutions is absorbed from the peri-
toneal cavity and may contribute to the
metabolic disturbances (Holmes and Shock-
ley 2000). Glucose and its degradation prod-
ucts may also irritate the peritoneal mem-
brane and aggravate its long-term alterations
(Davies et al. 2001, Witowski et al. 2001a).
Alternative osmotic agents such as icodex-
trin and amino acids have been developed
to avoid the harmful effects of glucose. The
other purpose of the present study was to
examine whether replacement of glucose
by icodextrin or amino acids in one daily
exchange is advantageous to glucose and
lipid metabolism and to peritoneal host de-
fence in PD patients.
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REVIEW OF THE LITERATURE
1. Principles of peritoneal dialysis
The peritoneum is used as a semipermeable
dialysis membrane in peritoneal dialysis
(Flessner 1991, Davies and Williams 2003).
The peritoneal membrane separates blood
and dialysis solution, and acts as a dialyser.
It is a heterogeneous and heteroporous
membrane with a complex anatomy and
physiology. Transfer of solutes occurs be-
tween blood vessels distributed within the
tissue underlying the peritoneum and the
dialysate (Flessner 1991). Solute removal
occurs down a concentration gradient,
whereas fluid removal occurs along an os-
motic gradient. Transport across the peri-
toneal membrane is linked to the permea-
bility of the capillaries and the vascular sur-
face area, which is determined by the
number of perfused capillaries in visceral
and parietal peritoneum.
2. Techniques of peritoneal dialysis
Access to the peritoneal cavity is achieved
by using a catheter. Peritoneal dialysis in-
volves  filling  the  peritoneal  cavity  with
dialysis solution, allowing the diffusion of
solutes and the removal of water to occur
during a certain dwell period, draining the
dialysate out and replacing it with fresh di-
alysis solution.
In continuous ambulatory peritoneal di-
alysis (CAPD) four to five exchanges per
day are carried out manually. The removal
of solute and water takes place steadily
around the clock. In automated peritoneal
dialysis (APD), the exchanges of dialysis
fluid are performed by a cycler mostly dur-
ing the night, and often dialysis fluid is left
in the peritoneal cavity also during the day.
CAPD has an advantage of simplicity over
APD, but APD with its different techniques
allows more effective solute removal and
offers social convenience with less bag
exchange during the day.
3. Outcome of peritoneal dialysis
Despite improvement in solution delivery
systems and dialysis solutions, the long-
term use of PD is often limited because the
ultrafiltration and solute clearance capacity
of the peritoneal membrane diminishes (He-
imburger et al. 1990, Davies et al. 1998a,
Smit et al. 2004). Depending on the defini-
tion, ultrafiltration failure is present in 10-
30% of PD patients at 2 years (Slingeneyer
et al. 1983, Heimburger et al. 1990).
Functional studies have shown that sol-
ute transport and peritoneal surface area
appear to increase in parallel with the dura-
tion of PD (Heimburger et al. 1999, Smit et
al. 2004). The increased diffusive transport
of small solutes leads to rapid glucose ab-
sorption and loss of the osmotic driving
force, resulting in decreased net ultrafiltra-
tion (Heimburger et al. 1999, Oreopoulos
and Rao 2001, Smit et al. 2004). High peri-
toneal permeability has been regarded as a
risk factor predicting both technical failure
and a higher mortality rate (Davies et al.
1998a, Davies et al. 1998b, Cueto-Manzano
and Correa-Rotter 2000). Morphological
studies have shown accumulation of fibrin
on the peritoneal surface, fibrosis ranging
from simple peritoneal sclerosis to scleros-
ing peritonitis, and vascular changes like
thickening and duplication of the basement
membranes, vasodilatation and neoangio-
genesis in the peritoneal membrane (Dob-
bie et al. 1994, Mateijsen et al. 1999, de
Vriese et al. 2001a).
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Severe or recurrent episodes of perito-
nitis may damage the peritoneal membrane
and lead to acute dropout from PD or to
gradually occurring changes in peritoneal
function (Davies et al. 1996, Piraino et al.
2005). Even though the incidence of peri-
tonitis has decreased in recent years, it still
remains a major complication of PD (Kim
et al. 2004, Piraino et al. 2005). Reduced
peritoneal immune function caused by con-
ventional dialysis solutions and poor nutri-
tional status predispose patients to perito-
nitis (Wang et al. 2003, Piraino et al. 2005).
The overall incidence of peritonitis is 1.1-
1.3 episodes/patient/year (Keane et al.
1996). Bacteria can gain access to the peri-
toneal cavity via the catheter lumen, via the
catheter tract, by migrating through the
bowel wall or with the bloodstream (Lee-
hey et al. 2001). The most common patho-
gens are staphylococcus epidermidis (30-
45%) followed by staphylococcus aureus
(10-20%) and streptococcus species (5-
Figure 1. Local aspects of bioincompatibility and their association with peritoneal function.
Bioincompatible, high glucose containing
dialysis solutions
Osmotic stress Oxidative stress AGE GDP
Alterations in cell function, chronic inflammation
FibrosisAngiogenesisImpaired host defencePeritonitis
Loss of ultrafiltration and solute removal
10%) (Leehey et al. 2001). Mortality and
catheter removal rates are high especially
in peritonitis caused by gram-negative and
multiple pathogens and by fungi (Tzamalou-
kas et al. 1993, Kim et al. 2004, Piraino et
al. 2005). In a retrospective analysis of Kim
et al. (2004) the mortality rate in peritonitis
caused by gram-negative pathogens was
3.7% compared with 1.4% in peritonitis
caused by gram-positive pathogens (P=NS),
whereas the catheter removal rate was
16.6% in gram-negative compared with
4.8% in gram-positive peritonitis (P<0.005).
Continuous exposure to bioincompati-
ble conventional dialysis solutions with high
glucose concentrations and hyperosmolali-
ty, low pH and a high amount of glucose
degradation products (GDP) may also dam-
age the peritoneal membrane (Liberek et al.
1993a, Witowski et al. 1995, Witowski et
al. 2001a, Mortier et al. 2004a, Mortier et
al. 2004b) (Figure 1). The causative role of
glucose in inducing changes in peritoneal
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function is supported by several studies:
Davies et al. (2001) found that an increase
in solute transport was preceded by in-
creased peritoneal exposure to glucose.
Further, in an animal model 3.86% glucose
solution caused impaired ultrafiltration, fi-
brosis and neoangiogenesis in the peritone-
um, whereas no major changes were seen
after infusion of Ringer lactate solution
(Krediet et al. 2000). The findings in the
peritoneal membrane during long-term PD
resemble the changes characteristic of dia-
betic vasculopathy and, furthermore, pa-
tients with peritoneal sclerosis had greater
cumulative glucose exposure than did the
controls (Mateijsen et al. 1999). Vascular
endothelial growth factor (VEGF) has been
shown to be involved in the pathophysiolo-
gy of diabetic vascular complications: De
Vriese et al. (2001b) showed that the hy-
perglycaemia-induced structural and func-
tional microvascular alterations were pre-
vented by neutralising anti-VEGF mono-
clonal antibodies. Furthermore, local pro-
duction of VEGF has been shown to in-
crease with time on glucose-based PD and
to decrease after switching to glucose-free
dialysis solution (Zweers et al. 2001).
Low pH especially in the presence of
lactate seems to lead to rapid intracellular
acidification and suppression of host de-
fence activity (Witowski et al. 1995, Mort-
ier et al. 2004b). Furthermore, uraemia is
associated with chronic low-grade inflam-
mation (Pritchard 1999, Jacobs et al. 2004),
which may contribute to structural and
functional alterations of the peritoneal mem-
brane. New dialysis solutions with a neu-
tral pH and osmolality seem to be beneficial
to host defence, but clinical evidence of
preventing peritonitis is still inconclusive
(Topley et al. 1996, Jörres et al. 1998, Jones
et al. 2001a, Fusshoeller et al. 2004,  Mort-
ier et al. 2004b).
Glucose degradation products which are
generated during heat sterilisation of the
dialysis solutions containing glucose seem
to contribute to peritoneal alterations
(Witowski et al. 2001a, Witowski et al.
2004). Furthermore, continuous absorption
of glucose and the uraemic environment
with high oxidative stress favours the for-
mation of advanced glycation end products
(AGE) (Mahiout et al. 1996, Miyata et al.
2000). AGE accumulation in the peritoneal
membrane seems to be associated with
interstitial fibrosis and microvascular scle-
rosis (Honda et al. 1999).
4. Assessing peritoneal clearances
and function
The transport of fluid and solutes varies
between different patients and also within
an individual with time. Therefore, regular
measurements of dialysis adequacy, ultra-
filtration and peritoneal characteristics are
necessary (Oreopoulos and Rao 2001).
The peritoneal clearances of urea and
creatinine can be calculated by collecting
the 24 h dialysate and measuring the dia-
lysate volume and concentrations of urea
and creatinine in the plasma and dialysate.
Daily ultrafiltration can be assessed from
the patients’ dialysis records or by collect-
ing the 24 h dialysate. To determine residu-
al renal function, all daily urine is collected,
and the clearance of urea and creatinine and
urine volume are measured.
The peritoneal equilibration test (PET)
is the traditional method to obtain informa-
tion on the rate of peritoneal transport of
small solutes and ultrafiltration capacity
(Twardowski et al. 1987, Davies and Wil-
liams 2003). In the PET test the concen-
tration of glucose in the initial inflow and
the concentrations of glucose and creati-
nine in the plasma and in the outflow after
4 hours’ dwell of a 2.27% glucose bag are
measured. The results are expressed as the
ratio of dialysate to the plasma creatinine
concentration, and as the ratio of dialysate
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glucose at 4 h to the dialysate glucose at
time zero. Due to the results the patients
can be divided into four transporter types:
high, high-average, low-average and low
transporters (Twardowski et al. 1987).
Kinetic modelling in dialysis refers to the
mathematical description of the transfer of
solute and water between the patient and
the dialysis solution (Flessner 1997). It can
be used to quantitate the amount of solute
and water transferred from the patient dur-
ing dialysis, and to predict necessary ad-
justments in the dialysis prescription (Fless-
ner 1997). Sophisticated computer models
to assess the peritoneal function have been
developed by all the major dialysis compa-
nies: PD ADEQUEST test (Baxter Health-
care, Deerfield, IL, USA), Peritoneal Func-
tion Test (Fresenius Medical Care) and the
PDC test (Personal Dialysis Capacity test,
Gambro, Sweden).
PD ADEQUEST can be used for calcu-
lating the indices of dialysis efficiency and
for the mathematical simulation of the re-
sults of various dialysis regimens (Vonesh
et al. 1999). It was initially based on the
Pyle-Popovich model in which solute mass
transport is described using a two-pool
compartment model (Popovich et al. 1981).
It was later modified to reflect key aspects
of the three-pore model of the peritoneal
membrane and ultrafiltration as described
by Rippe  and colleagues (Rippe et al. 1991).
Further, in PD ADEQUEST 2.0 solute mass
transfer area coefficients reflect their de-
pendence on dwell times and fill volumes
(Keshaviah et al. 1994, Waniewski et al.
1996, Vonesh et al. 1999).
Peritoneal function test (Fresenius Med-
ical Care) gives data on renal function, Kt/
V, creatinine clearance, water balance and
transport parameters, as well as on nutri-
tional state (Gotch and Keen 1995, Gotch
and Lipps 1997). The peritoneal barrier is
considered as an engineering black-box for
which the inputs (dialysate volumes, plas-
ma concentration) and outputs (dialysate
drain volume and concentration) are
known, but the actual physiological mech-
anisms are not included in the model for-
mation (Gotch and Keen 1995, Gotch and
Lipps 1997). A computer model is used to
find the set of parameters that result in the
best model fit to the patients’ data. The time
required for 50% equilibration between the
blood and the peritoneal cavity is used as a
surrogate for the mass transfer area coef-
ficient in order to categorise the patients
into the type of transporter described by
Twardowski (Twardowski et al. 1987).
In the Personal Dialysis Capacity test
(PDC, Gambro, Sweden) a computer pro-
gram based on the three-pore model is used
to describe peritoneal membrane transport
characteristics (Haraldsson 1995, Rippe
1997, Van Biesen et al. 2003). Due to the
three-pore model, the small pores with a
radius around 4 nm represent the major
pathway for small solutes. Macromolecules
are transported by convection through a few
large pores with a radius of >15 nm. The
smallest transcellular pores allow the pas-
sage of water. It is likely that aquaporins in
the capillaries represent the smallest pores.
The most important PDC test parameters
are the area parameter, the absorption rate
and the large pore flux (plasma loss). The
area parameter represents the unrestricted
area of the pores in all capillaries perfused
at a given time, normalised with respect to
the diffusion distance. The absorption rate
determines the final reabsorption rate of fluid
from the peritoneal cavity, when the glu-
cose gradient has dissipated, whereas the
large pore flux determinates the loss of pro-
tein to the dialysate. During the PDC test
day the CAPD patients have five exchang-
es of dialysis solution at standardised inter-
vals. In APD patients the test can be done
with a standardised APD program. Glucose,
urea, creatinine and albumin are analysed
from blood, dialysate and urine, and dialy-
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sis adequacy (residual renal function, total
and PD delivered Urea Kt/V, creatinine clear-
ance and ultrafiltration) and membrane char-
acteristics (the effective area of the perito-
neal membrane, absorption rate, plasma loss
and hydraulic conductance) are calculated.
Various dialysis regimens can be simulated
with the computer program.
5. Soluble factors in the dialysate
Macrophages, mesothelial cells and fibrob-
lasts are capable of producing various cy-
tokines and growth factors (Ruddle 1992,
Beavis et al. 1997, Lai et al. 1999, Yao et al.
2004a, Yao et al. 2004b). Soluble factors in
the dialysate seem to be mainly produced
locally in the peritoneal membrane (Koomen
et al. 1994, Zweers et al. 1999). They are
of large molecular sizes (e.g. hyaluronan)
or are bound to carrier proteins (e.g. sI-
CAM-1, TGF-β1, IL-6) in the circulation.
It is therefore unlikely that they could pass
the capillary walls of the peritoneal mem-
brane in significant amounts. Furthermore,
many investigators have shown higher con-
centrations of soluble factors in the dialysate
than in the plasma (Koomen et al. 1994,
Brauner et al. 1996, Zweers et al. 1999).
The network of cytokines, growth fac-
tors and adhesion molecules participating
in inflammation and host defence is very
complex. Several factors have many, partly
opposite, effects depending on the milieu and
other immune active factors. Furthermore,
gene polymorphism of cytokines seems to
have an influence on cytokine production,
host defence capacity, susceptibility to var-
ious diseases, and the severity of the illness
(Wilson et al. 1995). During the initial phase
of peritoneal host response, resident peri-
toneal macrophages are activated by micro-
organisms and their products (Faull 2000,
Mortier et al. 2004b) (Figure 2). Activated
cells release a variety of proinflammatory
cytokines, chemoattractants and prostag-
landins. Mesothelial cells become activated
and produce prostaglandins, chemotactic
Figure 2: Peritoneal host defence. ICAM= intercellular adhesion molecule, IL= interleukin,
LTB-4= leukotriene B4, MCP-1 monocyte chemoattractant protein-1, PG= prostaglandin,
TGF-β= transforming growth factor-beta, TNF-α= tumour necrosis factor-alpha, TXB2=
thromboxane B2, VEGF= vascular endothelial growth factor
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proteins and inflammatory cytokines and
growth factors (Topley and Williams 1994,
Brulez and Verbrugh 1995). However, sev-
eral factors such as IL-1 receptor antago-
nists and TNF soluble receptors released
by monocytes and polymorphonuclear leu-
kocytes may restrain inflammatory activa-
tion (Arend et al. 1991). Also the fibrob-
lasts are stimulated during the inflammato-
ry process (Hogaboam et al. 1998). It has
been shown that they can produce e.g. in-
terleukins, chemoattractants and growth
factors (Jörres et al. 1996, Beavis et al.
1997, Hogaboam et al. 1998, Witowski et
al. 2001b). Thus, they may also contribute
to leukocyte recruitment in the peritoneal
cavity and other inflammatory processes in
the peritoneal membrane.
Tumour necrosis factor-α (TNF-α) is
produced early in inflammatory processes
by e.g. macrophages and mesothelial cells
(Le and Vilcek 1987, Ruddle 1992, Yao et
al. 2004b). It has various immunological
functions and generates a cascade of other
mediators and upregulation of other cy-
tokines and adhesion molecules (Le and
Vilcek 1987, Ruddle 1992). Interleukin-6
(IL-6) is an important mediator of inflam-
mation (Akira et al. 1993). It is produced
by inflammatory cells, mesothelial and me-
sangial cells and in renal as well as in peri-
toneal fibroblasts (Akira et al. 1993). To-
gether with TNF-α and other inflammato-
ry transmitters, it stimulates the production
of adhesion molecules such as intercellular
adhesion molecule 1 (ICAM-1), which plays
an important role in inflammatory process-
es and host defence (Elsner et al. 1995, van
de Stolpe and van der Saag 1996). ICAM-1
is expressed by many cell types, e.g. by
leukocytes and vascular endothelial and
epithelial cells as well as by peritoneal mes-
othelial cells (Elsner et al. 1995, van de
Stolpe and van der Saag 1996, Yao et al.
2004a). It mediates the interaction of cells
with the extracellular matrix and other cells
(Elsner et al. 1995, van de Stolpe and van
der Saag 1996). A soluble form of ICAM-1
is shed from ICAM-1 shedding cells most
likely by proteolytic cleavage, and secreted
into the surrounding fluid (van de Stolpe
and van der Saag 1996). The same cy-
tokines that increase expression of mem-
brane-bound ICAM-1 are believed to in-
crease the shedding of sICAM from the cells
(van de Stolpe and van der Saag 1996, Tep-
po et al. 2001).  It has been shown that
transmigration of blood leukocytes into the
peritoneal cavity during uncomplicated di-
alysis and during peritonitis is related e.g.
to selective upregulation of ICAM-1 (Lib-
erek et al. 2004). ICAM-1 binds to hyaluro-
nan in a dose-dependent way (Teppo et al.
2001). Hyaluronan forms a critical compo-
nent of extracellular matrixes (Laurent and
Fraser 1992). It is present in tissues under-
going remodelling, and has an important role
in wound repair, adhesion and locomotion
of cells, and water homeostasis (Laurent
and Fraser 1992). Both peritoneal mesothe-
lial cells and fibroblasts can synthesise hy-
aluronan (Breborowicz et al. 1998). Its pro-
duction is stimulated by various cytokines
and growth factors (Laurent and Fraser
1992, Breborowicz et al. 1998). Cancer
antigen 125 (CA125) is an ovarian tumour
marker, which serves as an indicator of
mesothelial cell mass (Visser et al. 1995,
Ho-dac-Pannekeet et al. 1997). It can also
be used as a marker for the effects of peri-
tonitis on the peritoneum (Pannekeet et al.
1995). Vascular endothelial growth factor
(VEGF) and transforming growth factor-
beta (TGF-β) can be produced by e.g. peri-
toneal mesothelial cells (Ha et al. 2002).
TGF-β is vital to tissue repair, but may also
lead to fibrosis and scarring (Border and
Ruoslahti 1992). VEGF seems to play a
pivotal role in peritoneal angiogenesis and
hyperpermeability of the peritoneal mem-
brane (Zweers et al. 1999, van Esch et al.
2004). Furthermore, recent findings sug-
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gest that genetic polymorphism of VEGF
may have an impact on the longitudinal
change of peritoneal transport and survival
of PD patients (Szeto et al. 2004).
Peritonitis leads to excessive excretion
of various inflammatory mediators such as
TNF-α, IL-6 and hyaluronan (Pannekeet
et al. 1995, Brauner et al. 1996, Lai et al.
2000). Increased proliferation of fibroblasts
can also be induced by incubation with di-
alysate, as well as by incubation with vari-
ous growth factors and cytokines, and pre-
vented by their specific antibodies (Beavis
et al. 1997). This indicates that inflamma-
tion may play a role in the development of
structural changes in the peritoneal mem-
brane. Furthermore, Pecoits-Filho et al. have
shown  increased  plasma  and  dialysate
levels of IL-6 and VEGF in high/high-aver-
age transporters suggesting that inflamma-
tion and angiogenesis may be involved in
the pathophysiology of high peritoneal trans-
port status (Pecoits-Filho et al. 2002a).
6. Dialysis solutions
All dialysis solutions contain sodium, calci-
um, magnesium, chloride and lactate or bi-
carbonate as a source of buffer. Glucose
has traditionally been used as an osmotic
agent. Conventional dialysis solutions are
hyperosmolar and have an acidic pH, a high
concentration of glucose and GDPs lead-
ing to reduced biocompatibility, which is
regarded as an important cause of long-term
alterations in peritoneal function (Figure 1)
(Liberek et al. 1993a, Witowski et al. 1995,
Ha et al. 2000, Witowski et al. 2001a, Mort-
ier et al. 2004a, Mortier et al. 2004b).
Recently, dialysis solutions with a neu-
tral pH and a low content of GDPs have
been introduced to improve biocompatibil-
ity. Nowadays, neutral solutions with bi-
carbonate or a combination of lactate and
bicarbonate as a source of buffer are also
commercially available. Several studies sup-
port the enhanced biocompatibility of the
pH neutral solutions (Topley et al. 1996,
Jörres et al. 1998, Ha et al. 2000, Jones et
al. 2001a, Fusshoeller et al. 2004, Mortier
et al. 2004b, Williams et al. 2004). Also tech-
nical improvements such as three-compart-
ment bags to avoid the formation of GDP
have been shown to be beneficial (Cappelli
et al. 1999).
Several substances such as glycerol,
icodextrin and amino acids have been stud-
ied in order to find an appropriate osmotic
agent to substitute glucose from the dialy-
sis solutions. Glycerol has been proven to
be safe, but due to its low molecular weight
the osmotic gradient disappears rapidly lead-
ing to lower ultrafiltration compared with
glucose at equimolar concentrations (Smit
et al. 2000). Van Biesen et al. showed
that using a new dialysis solution containing
0.6 % amino-acid/1.4 % glycerol was safe
and well tolerated, and its ultrafiltration ca-
pacity was comparable to 2.27% glucose
solution (Van Biesen et al. 2004). Glucose
load was reduced, and CA125 levels in the
dialysate improved during the use of the new
solution (Van Biesen et al. 2004). Both ico-
dextrin and amino acids have been found
to be safe glucose-free osmotic agents,
which may also have other beneficial prop-
erties. They are discussed in detail below.
6.1. Glucose as osmotic agent
Glucose at variable concentrations has
traditionally been present as an osmotic
agent in the dialysis solutions. It is inex-
pensive and non-toxic. However, a consid-
erable part of the glucose is absorbed from
the peritoneal cavity, leading to unwanted
metabolic effects such as obesity, hyperin-
sulinism and insulin resistance (Holmes and
Shockley 2000). Glucose is also considered
to be harmful to the peritoneal membrane
(Davies et al. 2001). The causative role of
glucose in alterations in peritoneal mem-
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brane function has been described earlier
(Chapter 3).
6.2. Icodextrin as osmotic agent
Icodextrin (ID, Extraneal®, Baxter) is a
glucose polymer which acts as a colloid
osmotic agent and provides an improved
and sustained ultrafiltration (Peers and Gokal
1998). It is iso-osmolar (282 mOsm/kg),
but has a low pH of 5.1. Its safety and ef-
ficacy has been proven in large trials (Mis-
try et al. 1994, Plum et al. 2002). Allergic
skin reactions have been associated with
the use of  ID (Goldsmith et al. 2000). Plas-
ma levels of maltose tend to increase, and
levels of amylase and sodium tend to de-
crease during the use of ID without any
clinical symptoms (Plum et al. 2002). Epi-
sodes of sterile peritonitis have appeared in
icodextrin users since 2001. Excess cases
of sterile peritonitis between 2001 and 2003
were due to peptidoglycan contamination
of dialysate by Alicyclobacillus (Martis et
al. 2005).
Icodextrin has been shown to improve
fluid status, reduce blood pressure, extra-
cellular water and left ventricular mass
(Woodrow et al. 2000, Davies et al. 2003,
Konings et al. 2003) as well as to improve
glycemic control (Marshall et al. 2003) and
quality of life (Guo et al. 2002).
There is evidence that the lipid profile
improves during use of ID. Bredie et al.
(2001) showed a reduction in total choles-
terol and LDL cholesterol in 21 CAPD pa-
tients after 6 weeks’ use of ID as an over-
night dwell. Also HDL cholesterol declined
slightly, whereas no significant changes were
seen in free fatty acids or triglycerides
(Bredie et al. 2001). Sisca and Maggiore
(2002) showed that the use of one noctur-
nal exchange of ID was associated with a
marked reduction in triglycerides. Further-
more, Amici et al. (2001) noted lower se-
rum insulin levels and better insulin-sensi-
tivity in ID users than in a control group.
Several in vitro studies have assessed
the biocompatibility of icodextrin. Ha et al.
(2002) have shown that both high glucose
and glucose degradation products of dialy-
sis solutions induce vascular endothelial
growth factor (VEGF) and procollagen III
N-terminal peptide (PIIINP) secretion in
mesothelial cells, which was less pro-
nounced in the presence of ID, suggesting
enhanced biocompatibility of ID. The for-
mation of Amadori albumin, GDP and AGE
was reduced during ID in several studies
(Barre et al. 1999, Cooker et al. 1999, Post-
huma et al. 2001). Bajo et al. (2000) showed
greater ex vivo proliferation of mesothelial
cells taken from ID effluent than from glu-
cose effluent. However, some studies have
shown equally much cell culture cytotox-
icity with ID as with conventional glucose-
based solutions (Liberek et al. 1993b, Plum
et al. 1998, Posthuma et al. 2000). On the
other hand, Parikova et al. (2003) found
more signs of subclinical inflammation dur-
ing the use of ID than during the use of
glucose-based  solutions.  Furthermore,
Gotloib et al. (2002) found mesothelial dys-
plastic changes and lipid peroxidation in-
duced by icodextrin.
6.3. Amino acids as osmotic agent
Dialysis solutions containing amino acids
(AA) have been introduced to improve the
nutritional status in malnourished patients
and to reduce glucose load.  Amino-acid-
based solution (AA, Nutrineal®,  Baxter)
has a more physiological pH than the con-
ventional glucose-based solutions. As it does
not contain glucose, the formation of GDP
and advanced glycation end products
(AGE) can be avoided.
The malnutrition of PD patients is
caused by poor appetite, low protein intake,
loss of amino acids and other proteins into
the dialysate. Furthermore, the latest inves-
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tigations emphasise the role of inflamma-
tion in connection with malnutrition and
atherosclerosis (Stenvinkel et al. 2000, Pe-
coits-Filho et al. 2002b). Amino-acid-con-
taining dialysis solutions have been associ-
ated with modest nutritional benefits (Bru-
no et al. 2000). Misra and co-workers
found favourable nutritional effects in mal-
nourished patients during six-month use of
amino-acid solution (Misra et al. 1996). In
another study, Jones et al. (1998) found
nutritional benefit especially in hypoalbumi-
naemic patients undergoing one to two dai-
ly exchanges of amino-acid solution during
three months. The effects on the lipid pro-
file have been controversial. Misra et al.
(1997) found no effect on dyslipidaemia
during 6 months’ use of 1.1% amino-acid
solution, whereas Brulez et al. (1999)
showed decreasing fat mass and triglycer-
ide levels, but no change in cholesterol or
cholesterol fractions during 2 months’ use
of AA. In a study of Young et al. (1989)
cholesterol decreased in seven of eight pa-
tients during 12 weeks’ use of AA.
Previous studies have shown that ami-
no-acid-based solution may cause less peri-
toneal irritation than glucose-based solution.
Mesothelial ultrastructure, viability and pro-
tein synthesis were better preserved with
amino-acid-based dialysis solution com-
pared with conventional dextrose-based
solution, whereas IL-6 secretion of cultured
mesothelial cells increased (Chan et al.
2003). Brulez et al. (1996) demonstrated
increased viability and phagocytic capacity
in peritoneal macrophages incubated in AA-
containing dialysis solution compared with
conventional glucose-based solution. Fur-
thermore, in an experimental in vivo study,
mesothelial damage and vascular changes
could be avoided in rabbits, when amino
acids were used instead of glucose as os-
motic agents in dialysis solutions (Garosi
et al. 1998).
7. Outcome of peritoneal dialysis
patients
According to the latest report of the United
States Renal Data System, the remaining
life-expectancy of dialysis patients was only
one-third to one-sixth of that of the general
population (USRDS 2005). Cardiovascular
diseases are common among peritoneal di-
alysis patients. In the year 2000, 54% of
the deaths of PD patients in Finland were
due to cardiovascular diseases (Finnish
Registry for Kidney Diseases, Annual re-
port 2000). Diabetes and dyslipidaemia are
well known risk factors of cardiovascular
diseases, which are the main causes of death
among uraemic patients. Patients with end-
stage renal diseases (ESRD) are insulin re-
sistant (DeFronzo et al. 1981) and have
unfavourable lipid profiles, e.g. elevated
cholesterol levels, hypertriglyceridaemia,
and low high-density lipoprotein (HDL) lev-
els (Lindholm and Norbeck 1986, Chen et
al. 2001).
Hyperlipidaemia with PD has been at-
tributed to the continuous absorption of glu-
cose (Lindholm and Norbeck 1986, Holm-
es and Shockley 2000). It has been sug-
gested that approximately 60-80% of the
glucose installed into the peritoneal cavity
is absorbed; this corresponds to 100-300g
of glucose intake per day (Holmes and
Shockley 2000). Absorption of glucose
leads to a daily calorie load of  400-1000
kcal, which contributes to obesity. Espe-
cially the use of dialysis solutions with high
glucose concentrations seems to lead to
sustained hyperinsulinaemia and reduced
insulin sensitivity and to contribute to an
unfavourable lipid profile. Lindholm and
Norbeck (1986) showed that very low den-
sity lipoprotein (VLDL) triglycerides, VLDL
cholesterol and serum triglycerides, and
changes in these variables correlated with
the amount of glucose in the dialysates. This
finding supports the hypothesis that the
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continuous peritoneal absorption of glucose
during CAPD contributes to potentially
atherogenic changes in serum lipids and li-
poproteins (Lindholm and Norbeck 1986).
Insulin can be administrated intraperitoneally
to diabetic CAPD patients. Intraperitoneal
insulin mimics physiological insulin deliv-
ery and induces better glycaemic control,
but seems to be associated with lowered
HDL cholesterol and Apoprotein A-1 levels
(Nevalainen et al. 1999).
There are two larger studies assessing
the influence of small-solute clearance on
the outcome. In the CANUSA study, pa-
tients who maintained higher small-solute
clearance over the study period (average
follow-up of two years) had better out-
comes (CANADA-USA (CANUSA) Perito-
neal Dialysis Study Group 1996). This ad-
vantage was attributable to maintained re-
sidual renal function. There was no upper
limit beyond which further increases in
clearance were not associated with im-
proved outcome. Contrary to this, the ADE-
MEX study did not show any survival ad-
vantage in maintaining a total creatinine
clearance above 60L/1.73 m2 compared
with less than 50L/1.73 m2 (Paniagua et al.
2002).
Hyperphosphataemia  is a frequent and
important cardiovascular risk factor in pa-
tients with chronic kidney diseases (Can-
nata-Andia and Rodriguez-Garcia 2002).
High phosphate levels may contribute to
vascular calcification in many ways: by in-
ducing proliferation and differentiation of
endothelial vascular cells into osteoblast-like
cells, by promoting calcium-phosphate dep-
osition in pre-formed endothelial plaques
and by worsening secondary hyperparath-
yroidism  (Cannata-Andia and Rodriguez-
Garcia 2002). The prevalence of peripheral
arterial disease and medial arterial calcifi-
cation is high in dialysis patients (Leskinen
et al. 2002). Malnutrition is also a common
problem among PD patients (Young et al.
1991). It can be caused by poor appetite
and low protein intake as well as by loss of
amino acids and other proteins into the dia-
lysate. Furthermore, a connection between
inflammation, malnutrition and atheroscle-
rosis in chronic renal failure has been found
recently (Stenvinkel et al. 2000, Pecoits-
Filho et al. 2002b). Low albumin is a strong
predictive factor for mortality in CAPD
(Cueto-Manzano et al. 2001).
Based on several analyses that have com-
pared the outcomes of PD and haemodial-
ysis (HD),  the mortality for the first years
of RRT seems to be the same for HD and
PD when identical types of patients are
compared (Nolph 1996, Fenton et al. 1997,
Collins et al. 1999, Maiorca and Cancarini
2000, Gokal 2002). Short-term PD has even
been associated with superior outcomes
compared with HD (Fenton et al. 1997,
Collins et al. 1999). However, Bloember-
gen et al. showed a 19% higher risk of
mortality among PD than among HD pa-
tients (Bloembergen et al. 1995).
8. Assessing the insulin sensitivity
Hyperinsulinaemia and insulin resistance are
common in uraemic patients (DeFronzo et
al. 1981).
There are numerous tests for assessing
insulin sensitivity: In the oral glucose toler-
ance test, plasma glucose and insulin con-
centrations are measured after a standard-
ised oral glucose load, and a glucose-insu-
lin ratio is calculated (Del Prato et al. 1986).
This test has many disadvantages, such as
variability in the gastrointestinal absorption
of glucose, as well as poor reproducibility.
Other insulin sensitivity tests include the
insulin suppression test and hyperglycae-
mic clamp techniques, both of which are
restricted to laboratory circumstances (Del
Prato et al. 1986).
The euglycaemic hyperinsulinaemic
clamp technique  is considered to be the
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standard test for measuring insulin sensi-
tivity (DeFronzo et al. 1979). The goal of
the euglycaemic clamp is to acutely raise
and maintain the plasma insulin concentra-
tion by a given amount while holding the
plasma glucose concentration constant at a
basal level with a continuos infusion of glu-
cose. At unchanged plasma glucose con-
centrations, the amount of glucose required
to maintain euglycaemia equals the whole-
body disposal of glucose.  This technique
offers major advantages, such as avoiding
hypoglycaemia with its potential hazards and
complex neuroendocrine response. The
euglycaemic clamp is nevertheless restricted
to laboratory circumstances, because it re-
quires a high input of time and expenses,
sophisticated equipment and trained person-
nel. Thus, simpler methods for measuring
insulin sensitivity have been developed for
clinical use.
In the short insulin tolerance test (ITT)
the rate of glucose disappearance is meas-
ured in arterialised blood during the first 15
minutes after a bolus of short-acting human
insulin. The KITT represents the percentage
decline in logarithmically transformed plas-
ma glucose per minute. Because the hor-
mones that counter-regulate hypoglycaemia
are secreted only after this time, it is assumed
that the KITT represents the insulin-mediated
glucose uptake by the tissues. Akinmokun
et al. (1992) have shown that ITT is safe
and reproducible and correlates strongly with
the euglycaemic clamp. Calculating the Quan-
titative Insulin Sensitivity Check Index
(QUICKI) is a useful non-invasive method
to assess insulin sensitivity (Perseghin et al.
2001). It has a good correlation with the
clamp-based index of insulin sensitivity
(Perseghin et al. 2001).
9.  Insulin sensitivity and substrate
oxidation in peritoneal dialysis
patients
Insulin resistance in uraemia is based on
reduced tissue sensitivity to insulin (De-
Fronzo et al. 1981). The basal insulin levels
of CAPD patients are raised, and each dia-
lytic exchange is associated with a marked
insulin response (De Santo et al. 1979).
However, some investigators have shown
improved insulin sensitivity during CAPD
when compared to chronic uraemia (Cas-
tellino et al. 1999, Kobayashi et al. 2000),
whereas others have found that glucose
intolerance persists during CAPD (Lind-
holm and Karlander 1986).
In CAPD patients, basal glucose oxida-
tion is increased, and basal lipid oxidation
is decreased, when compared to normal
controls (Castellino et al. 1999). Harty et
al. (1995) found no significant difference
in resting energy expenditure between fast-
ed CAPD patients and healthy controls, but
unlike in the control group, blood glucose
was maintained during prolonged fasting in
the CAPD patients. Glucose uptake repre-
sents a significant proportion of daily sub-
strate uptake in CAPD patients (De Santo
et al. 1979, Holmes and Shockley 2000).
They show preferential utilisation of glu-
cose as an energy substrate, and a lower
rate of lipid oxidation. Similar changes can
be observed in healthy persons maintained
on high dietary carbohydrate intake (Si-
monson and DeFronzo 1990).
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AIMS OF THE STUDY
1. to evaluate whether dialysis adequacy
or characteristics of the peritoneal mem-
brane are associated with markers of in-
flammation and fibrosis in the dialysate
(I),
2. to study how dialysis adequacy and
characteristics of the peritoneal mem-
brane change during a one-year follow-
up, and whether the changes are asso-
ciated with markers of inflammation and
host defence in the dialysate (II),
3. to measure whether different systemic
or local markers of inflammation pre-
dict the outcome of peritonitis, and
whether they are normalised in parallel
with the clinical recovery (III),
4. to evaluate the impact of two glucose-
free dialysis solutions on peritoneal in-
flammation and host defence (IV),
5. to study the impact of two glucose-free
dialysis solutions on energy, glucose and
lipid metabolism and on insulin resist-
ance compared with solely glucose-
based solutions (V).
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MATERIALS AND METHODS
1.  Subjects
Part 1. Influence of dialysis adequacy,
characteristics of the peritoneal
membrane and peritonitis on
inflammatory and fibrotic parameters
in the dialysate (I-III)
1.1. Association of dialysis adequacy
and characteristics of the peritoneal
membrane with soluble factors in the
dialysate, and their changes during
a one-year follow-up (I,II)
All patients in the PD ward who had been
on PD for at least 3 months between Sep-
tember 1999 and February 2000 were en-
rolled. Exclusion criteria were severe anae-
mia and malnutrition, malignancies, active
systemic inflammation and the use of cor-
ticosteroids or other immune-suppressive
drugs. If the patients had had peritonitis,
the measurements of dialysis adequacy and
soluble factors were not performed until 4
weeks after completing the treatment of
peritonitis.
Data on the subjects of the cross-sec-
tional and follow-up study are shown in
Table 1. Forty stable PD patients partici-
pated in a cross-sectional study. Twenty-
one (52.5%) patients had diabetic nephrop-
athy, 2 (5%) SLE nephritis with no other
active systemic manifestations, 13 (32.5%)
different kinds of primary renal disorders,
and 4 (10%) ESRD of unknown aetiology.
Twenty  patients were re-examined after
6.4 ± 0.1 and 12.1 ± 0.1 months. The oth-
er 20 patients dropped out for several rea-
sons: e.g. kidney transplantation, moving
away, transfer to haemodialysis, or death.
1.2. Inflammatory parameters during
and after peritonitis and their
association with the outcome of
peritonitis (III)
All suitable patients displaying typical symp-
toms and findings of acute peritonitis (ab-
dominal pain, cloudy dialysate with leuko-
cyte count exceeding 100×106/L (of which
at least 50% are polymorphonuclear neu-
trophils), positive dialysate bacterial culture)
between September 1999 and November
2000 were enrolled. The diagnosis of peri-
tonitis required the presence of at least two
of the three findings mentioned above. Ex-
clusion criteria were severe anaemia and
malnutrition, malignancies, active systemic
Table 1 : Clinical characteristics of the patients in the studies I-II
Cross-sectional study Follow-up study
N 40 20
Age (years) 52.5±2.2 50.8±3.3
Male: female (N) 25 : 15 14 : 6
Time on PD at the start (months) 13.9±2.9 14.6±6.6
Treatment modality APD 13 (32.5%) 10 (50.0%)
                               CAPD 27 (67.5%) 10 (50.0%)
All values are mean ± SEM.
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inflammation and the use of corticosteroids
or other immune-suppressive drugs. Data
on the 36 patients participating in the study
are shown in Table 2. Sixteen patients had
diabetic nephropathy, 14 a primary renal
disorder, and 6 patients ESRD of unknown
origin.
Table 2: Clinical characteristics of the
patients in the study III
N 36
Age (years) 55.3±2.4
Male: female (N) 17 : 19
PD-duration (months) 19.9±3.2
treatment modality: APD 9
CAPD 27
All values are mean ± SEM.
The treatment was started with a combina-
tion of cephalothin and netilmycin. The sub-
sequent therapy with antibiotics and treat-
ment duration (2-4 weeks) were tailored to
the culture results according to the ISPD
guidelines from 1996 (Keane et al. 1996).
All patients were on CAPD during the treat-
ment of peritonitis.
Part 2. Influence of glucose-free
dialysis solutions on host defence and
on metabolism (IV,V)
All suitable patients who started CAPD treat-
ment during January 2001-2003 were en-
rolled. Exclusion criteria were type I diabe-
tes, severe anaemia or malnutrition, thera-
py with corticoid-steroids or other immune-
suppressive drugs, malignancies or signs
of systemic inflammation. Twenty-two pa-
tients who had been on PD for six months
or less participated in the study. Data on
the patients are shown in Table 3. All pa-
tients were on continuous ambulatory peri-
toneal dialysis (CAPD). Six patients had
diabetic nephropathy, 9 patients a primary
renal disorder and 7 patients ESRD of oth-
er or unknown origin. Four patients used
intraperitoneal insulin and one patient was
on oral diabetes medication.
Table 3: Clinical characteristics of the
patients in the studies IV-V
N 22
Male: Female (N ) 18 : 4
Age (years) 60.7±2.3
PD-duration (months) 3.6±0.3
All values are mean ± SEM.
2. Study designs
Part 1. Influence of dialysis adequacy,
characteristics of the peritoneal
membrane and peritonitis on
inflammatory and fibrotic parameters
in the dialysate (I-III)
2.1. Association of dialysis adequacy
and characteristics of the peritoneal
membrane with soluble factors in the
dialysate, and their changes during a
one-year follow-up (I,II)
In the cross-sectional study, a Personal
Dialysis Capacity (PDC) test (Gambro,
Sweden) was performed in 40 patients to
measure dialysis adequacy, nutritional sta-
tus and membrane characteristics. During
the PDC test day, dialysate from the over-
night dwell and 24 h collection was obtained
for the analysis of tumour necrosis factor
alpha (TNF-α), transforming growth fac-
tor beta-1 (TGF-β1), interleukin-6 (IL-6),
hyaluronan (HA) and soluble intercellular
adhesion molecule-1 (sICAM-1).  Further-
more, IL-6 was measured from the serum
of 22 patients. Twenty  patients were re-
examined after 6.4 ± 0.1 and 12.1 ± 0.1
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months with the intention of finding out the
changes in peritoneal function and levels of
the soluble factors in the dialysate and their
potential correlation. A PDC test was per-
formed, and dialysate was collected for
analysis of IL-6, CA125, sICAM-1 and HA
during the two additional test days. The
samples were stored at –20° C until ana-
lysed.
2.2. Inflammatory parameters during and
after peritonitis and their association with
the outcome of  peritonitis (III)
Samples of dialysate for the analysis of sI-
CAM-1, hyaluronan  and IL-6 were ob-
tained at the onset of peritonitis, on day four,
at the end of the treatment with antibiotics,
and two months after the onset of peritoni-
tis. The first sample was taken in connec-
tion with the hospitalisation from a dwell
lasting at least 4 hours. All other samples
were obtained from overnight dwells. The
samples were stored at –20° C until ana-
lysed. Serum CRP and dialysate leukocyte
count were measured on a daily basis (days
1-4) during the acute episode of peritonitis.
Part 2. Influence of glucose-free
dialysis solutions on host defence and
on metabolism (IV,V)
The design of the study is shown in Figure
3. During the eight-week study periods the
patients underwent one daily exchange of
icodextrin (ID, Extraneal®, Baxter) or ami-
no-acid-based (AA, Nutrineal®, Baxter)
dialysis solution in a random order. Twelve
patients started with ID (overnight dwell)
and 10 patients with AA (one daytime dwell).
Conventional glucose containing lactate-
based solutions were used for the other three
exchanges. The glucose concentrations
varied according to the individual need for
dialysis and ultrafiltration. After complet-
Figure 3: Study design (Studies IV and V).
Test =analyses of blood and dialysate, calorimetry, short insulin tolerance test.
AA= amino acid based dialysis solution, ID= icodextrin based dialysis solution
8 weeks AA
N=10
8 weeks wash out
8 weeks ID
N=12
8 weeks ID
N=8
8 weeks AA
N=10
test1
test2 test3 test4
test2 test3 test4
test1
calorimetry
calorimetry
calorimetrycalorimetry
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ing the first study period, the patients en-
tered a wash-out period of eight weeks
(solely glucose-based solutions) and were
then switched to the other study solution.
Metabolic analyses (blood analyses, in-
direct calorimetry and short insulin toler-
ance test)  were performed, and dialysate
samples (in order to analyse CA125, sI-
CAM-1, HA, IL-6 and TNF-α) were ob-
tained from an overnight dwell at the be-
ginning and end of the study periods. Indi-
rect calorimetry was performed also after
one weeks’ use of ID and AA in order to
measure acute changes in substrate oxida-
tion. The analyses were done after 12 h of
fasting during the night dwell before the first
morning exchange of dialysis solution. The
measurements at the beginning of the study
period were compared to measurements
after eight weeks’ use of ID and AA, re-
spectively. Calorimetry and measurements
of HbA1c and serum lipids were performed
also after eight weeks of simultaneous use
of ID and AA in eight patients.
3. Methods
3.1. Estimating dialysis adequacy and
peritoneal function: PDC test
In the Personal Dialysis Capacity (PDC) test
(Gambro, Sweden) a computer program
based on the three-pore model is used to
describe characteristics of peritoneal mem-
brane transport (Haraldsson 1995, Rippe
1997, Van Biesen et al. 2003). During the
PDC test, all patients were on CAPD and
used five exchanges of 1.5-2 L glucose-
containing dialysis solution at standardised
intervals. The glucose concentrations var-
ied according to the standard program of
the individual patient. Glucose, urea, creat-
inine and albumin were analysed from
blood, dialysate and urine to calculate nu-
tritional status, dialysis adequacy (residual
renal function, total and PD delivered Urea
Kt/V, creatinine clearance and ultrafiltration)
and membrane characteristics (the effec-
tive area of the peritoneal membrane, ab-
sorption rate, plasma loss and hydraulic
conductance).
3.2. Indirect calorimetry
Indirect calorimetry was performed during
30 min to estimate net rates of carbohy-
drate and lipid oxidation and their changes
during the use of non-glucose-containing
dialysis solutions (Ferrannini 1988). A com-
puterized open-circuit system was used to
measure gas exchange through a transpar-
ent 25-litre plastic canopy (Deltatrac, Da-
tex, Finland). The metabolic monitor cal-
culates carbon dioxide production and ox-
ygen consumption from the differences in
gas concentration measured between up-
stream and downstream flows in the cano-
py. Flow is measured by the air-dilution
method, carbon dioxide concentration by a
conventional  infrared detector, whereas
oxygen concentration is measured by a fast
differential paramagnetic oxygen sensor.
The effect of humidity is eliminated by us-
ing a semipermeable tubing system, which
balances the water vapour fraction of the
gases with the ambient air. The carbon di-
oxide concentration of the room is auto-
matically re-measured every 30 min to avoid
errors caused by drift in room-air carbon
dioxide concentrations. The monitor has a
precision of 2.5% for oxygen consumption
and 1% for carbon dioxide production.
Respiratory quotients (RQ) were measured,
and glucose (GOX) and lipid (LOX) oxida-
tion rates as well as energy expenditure (EE)
values were calculated using the constants
given by Ferrannini. Urinary excretion is the
predominant (>90%) mechanism of nitro-
gen removal. Because the residual renal
function of the dialysis patients is only min-
imal, the nitrogen production was set at a
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constant of 11g/day, as the glucose and lip-
id oxidation were calculated, and protein
oxidation was not analysed. Respiratory
quotients (RQ) are given as non-protein RQ
(nRQ) to avoid the eventual error of failure
to measure exact protein disappearance.
3.3. Short insulin tolerance test and
QUICKI
The short insulin tolerance test was per-
formed to measure insulin sensitivity (Ak-
inmokun et al. 1992). Two intravenous can-
nulas were inserted, one in a deep cubital
vein and the other in a retrograde position
in a dorsal vein of the contralateral hand.
The hand was kept in a heated (+55°C) box
to achieve arterialisation of venous blood.
After a baseline period of 20-30 minutes
fasting plasma glucose was measured
twice, and thereafter an intravenous bolus
of short-acting insulin (0.1 IU/kg) was giv-
en. Arterialised blood samples for the meas-
urement of plasma glucose level were
drawn every minute 3-15 minutes after the
insulin bolus. The percentage decline in log-
arithmically transformed plasma glucose per
min was calculated by least square analysis
and expressed as the KITT-value (%/min).
The Quantitative Insulin Sensitivity
Check Index (revised QUICKI with inclu-
sion of FFA) was calculated using the fol-
lowing formula: 1/[log(insulin µU/mL)
+log(gluc mg/dL)+log(FFA mmol/L)]
(Perseghin et al. 2001).
3.4. Assays
3.4.1. Dialysate samples
Dialysate creatinine levels were measured
by modified Jaffe reaction (Jaffe correc-
tion for the glucose content), urea levels
by glutamate hydrokinase, and glucose by
the hexokinase method using a Hitachi 911
E Automatic Analyser and SYS 2 BM Hi-
tachi reagents (Boehringer Mannheim, Ger-
many). Albumin was measured by an im-
munoturbidimetric method. Dialysate leu-
kocytes were counted with an automatic
blood cell counting analyser (Advia 120,
Byer).
Dialysate concentrations of soluble
ICAM-1 were analysed by high-sensitive
ELISA (the overall intra-assay coefficient
of variation (CV) of  5.6% and overall in-
ter-assay CV of 7.8%), Bender Med Sys-
tems, Vienna, Austria, IL-6 (intra-assay CV
of 6.1-4.0%, inter-assay CV 14.1-9.3%)
and TNF-α (intra-assay CV 8.2-5.1%, in-
ter-assay CV 9.4-5.7%) by radioimmu-
noassays. CA125 was quantitated with an
immunoenzymometric assay (Immuno1®,
Bayer, Tarrytown, NY). Detection limit of
the assay is 0.9 kU/L. In the concentration
range 15 - 500 kU/L inter-assay CV is <4%
and intra-assay CV <3%. HA was deter-
mined by ELISA (Corgenix, USA) with in-
tra- and inter-assay CV of 4.2-4.7% and
5.7-6.2%, respectively. TGF-β1 of acid-
activated (0.1N HCl, +22°C, 10 min) and
neutralised samples (detection level 30 ng/
L) was analysed by EIA (Vesaluoma et al.
1999). Natural human TGF-β1 was used
as standard (Code BDPI, R&D Systems,
London, UK).
The assays that were used showed no
detectable cross-reactivity with any other
cytokines or adhesion molecules.
3.4.2. Serum samples
Radioimmunoassay (RIA) with a measur-
ing range of 0.01-10 mg/L was used to
measure sensitive CRP in serum (mean of
normal±SD: 1.1±0.3 mg/L) (Teppo et al.
2003). The levels frequently exceeded 10
mg/L demanding repeated dilutions of the
samples affecting the precision of the anal-
yses. Therefore, if the levels of sensitive
CRP exceeded 10mg/L, the samples were
re-measured by a Hitachi 911 analyser us-
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ing reagents from Roche; in such cases this
value is reported.
Total cholesterol, HDL cholesterol and
triglycerides were analysed with an enzy-
matic method, and LDL cholesterol was
calculated using the  Friedewald formula.
Albumin was measured by an immunotur-
bidimetric method. Serum creatinine and
urea levels were measured by enzymatic
methods. A glucose oxidation method was
used to measure plasma glucose (Beckman
Glucose analyzer II, Beckman, Fullerton,
Calif., USA). Glycosylated haemoglobin
HbA1c (normal range 4-6%) was deter-
mined by high-pressure liquid chromatog-
raphy (HPLC). Insulin was measured by
using the Wallac AutoDELFIAtm insulin kit
(normal values 6.0-27mU/L). Free fatty
acids (FFA) were analysed by an enzymatic
calorimetric method (Wako NEFA C, Wako
chemicals USA, Inc. Richmond VA23237,
USA).
4. Statistical analyses
SAS (SAS Institute Inc. Cary, NC) and
StatsDirect Statistical Software were used
for statistical analyses of the results. The
Mann Whitney U-Test was used to com-
pare two independent groups with each oth-
er, and Spearman’s  rank correlation test to
correlate different variables with each oth-
er. Paired samples T-test was used to com-
pare parametric variables in paired analy-
ses of the same patients. Wilcoxon Signed
Rank test was used when non-parametric
variables were compared pair-wise in the
same individuals. All values are expressed
as means ± SEM or as medians with [range]
and as medians with quartiles and ranges in
figures. Probability values less than 0.05
were considered statistically significant.
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RESULTS
Part 1. Influence of dialysis adequacy,
characteristics of the peritoneal mem-
brane and peritonitis on inflammatory
and fibrotic parameters in the dialys-
ate (I-III)
1. Association of dialysis adequacy
and characteristics of the peritoneal
membrane with soluble factors in
the dialysate (I)
The concentrations of the soluble factors
were higher in overnight dwells than in 24 h
collections. Soluble factors in the dialysate
showed no direct correlation with measure-
ments of dialysis adequacy, except IL-6,
which correlated inversely with total urea Kt/
V. Plasma loss correlated with area, PD de-
livered creatinine clearance and with TNF-
α, hyaluronan and sICAM-1 in 24h dia-
lysate. IL-6 in 24 h collection of dialysate
was significantly higher in patients who had
previously had peritonitis than in patients with
no history of peritonitis (54.5 ± 8.9 [7.0-
150.0] vs. 21.0 ± 6.2 [1.0-98.0] ng/L, P =
0.02) and further, IL-6 showed a positive
correlation to the number of previous epi-
sodes of peritonitis (r=0.42, P<0.01). Dia-
lysate sICAM-1, IL-6, TNF-α and HA corre-
lated with each other. Concentrations of IL-6
in serum were significantly lower than the
concentrations in the 24 h dialysate (13.3±2.0
ng/L vs. 42.9±7.3 ng/L, P<0.0001).
2. Changes of dialysis adequacy, char-
acteristics of the peritoneal membrane
and soluble factors in the dialysate
during a one-year follow-up (II)
Serum albumin declined during the one-year
follow-up (from 31.3±0.8 to 30.8±0.8 at 6
months and to 29.4± 0.9 g/L at 12 months,
P=0.005) but BMI remained stable. The
measurements of dialysis adequacy and char-
acteristics of the peritoneal membrane are
shown in Table 4. There were no major
Table 4: Dialysis adequacy and characteristics of the peritoneal membrane during the one-
year follow-up (Study II)
start 6 months 12 months
Area cm/1.73 m2 16260±1415 16404±1367 18421±1632
Absorption rate mL/min/1.73 m2 2.04±0.24 2.45±0.25 2.20±0.23
Plasma loss mL/min/1.73 m2 0.098±0.010 0.102±0.011 0.102±0.012
Total crea clearance mL/min/1.73 m2 7.67±0.48 7.49±0.53 7.14±0.37
PD crea clearance mL/min/1.73 m2 4.47±0.16 4.52±0.23 4.72±0.18
Total urea Kt/V /week 2.23±0.12 2.19±0.15 2.09±0.10
PD-urea Kt/V /week 1.42±0.06 1.46±0.09 1.49±0.08
Ultrafiltration mL 802±168 648±145 946±255
RRF mL/min/1.73 m2 3.20±0.54 2.97±0.58 2.42±0.45
Glucose concentration g/L 21.21±0.93 21.25±0.80 21.53±0.78
Icodextrin L 0.90±0.21 1.11±0.22 1.30±0.20*
Patients (N) 10 12 14
Dialysis solutions L/day 13.2±1.1 13.7±1.2 13.9±1.2 *
Crea = creatinine        RRF= residual renal function      All values are mean ± SEM.     * P<0.05
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changes in the parameters of dialysis ade-
quacy, but the daily volume of the dialysis
solutions increased, and further, an increas-
ing number of patients needed icodextrin
to achieve sufficient ultrafiltration. Charac-
teristics of the peritoneal membrane did not
show any significant changes during the fol-
low-up.
The appearance rate of IL-6 in the
dialysate increased significantly during the
one-year follow-up (419.8±63.3 vs.
784.1±136.4 vs. 1149.3±252.2 ng/24h,
P=0.006). Further, IL-6 at the start of the
study correlated with the subsequent decline
in serum albumin concentration. Neither sI-
CAM-1 nor HA showed any significant
changes during the follow-up. The appear-
ance rates of CA125 measured after 12
months of follow-up were higher in patients
using icodextrin in one daily exchange at the
start and throughout the study (P=0.03).
They increased during the follow-up
(P=0.048) in this group of patients, but de-
creased slightly in patients using only con-
ventional dialysis solutions.
Six patients experienced a single episode
of peritonitis during the follow-up. The sol-
uble factors in the dialysate, parameters of
dialysis adequacy, or membrane character-
istics did not differ significantly between
the patients with and without peritonitis
during the follow-up.
3. Inflammatory parameters during
and after peritonitis and their
association with the outcome of
peritonitis (III)
There was bacterial growth in all but one
sample of dialysate at the onset of peritoni-
tis. Coagulase-negative staphylococcus spe-
cies were the most common pathogens (10/
36 episodes), followed by streptococcus
viridans (7/36 episodes) and staphylococ-
cus aureus (6/36 episodes).
The results were analysed according to
the outcome. Good outcome (N=28) was
defined as a disappearance of symptoms
and signs of peritonitis during the treatment
with antibiotics. Seven of these patients had
a relapse/re-infection. Eight patients did not
respond to the antibiotic therapy (poor out-
come), seven of them were transferred to
haemodialysis, and one patient died.
Most episodes of peritonitis caused by
streptococcus viridans (7/7) or coagulase-
negative staphylococci (8/10) had a good
outcome, whereas peritonitis caused by
multiple or intestinal microbes was compli-
cated in approximately a half of the cases.
Both CRP (175.8±34.1 vs. 71.3±15.5
mg/L, P=0.014) and leukocytes (4086±
1839 vs. 327±84 × 106/L,  P=0.008) on day
four of the acute episode of peritonitis were
significantly higher in patients with a poor
outcome than in patients with an uncom-
Table 5: Soluble factors in dialysate during the acute episode of peritonitis in patients
completing the antibiotic treatment (Study III)
Onset Day 4 End of the treatment
sICAM-1 (µg/L) 13.4±2.3 10.1±1.3* 4.3±0.7 ***
HA (µg/L) 3136.7±415,5 1410.2±224.1* 614.1±161.7 ***
IL-6 (ng/L) 735.2±67.6 529.1±40.8** 331.0±43.2 ***
*      P = 0.0005
**    P=0.0001
***  P<0.0001
All values are mean ± SEM.
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Figure 5: IL-6 in the dialysate two months
after the onset of peritonitis compared to
values of patients with no history of
peritonitis (Study III). The values are
expressed as minimum-[lower quartile-
median-upper quartile]-maximum.
Figure 4: sICAM-1 and HA in the dialysate at the end of the antibiotic treatment of peritonitis
in patients with a good outcome and a relapse/re-infection compared to patients with a good
outcome and no relapse/re-infection in the study III. The values are expressed as minimum-
[lower quartile-median-upper quartile]-maximum.
plicated clinical course. When CRP exceed-
ed 100mg/L or the dialysate leukocytes
exceeded 350 × 106/L on day four, the out-
come was poor in 75% of the cases.
Dialysate concentrations of IL-6, sI-
CAM-1 and HA were higher at the onset
and on day four of peritonitis than at the
end of the treatment with antibiotics (Table
5). The concentrations of sICAM-1, HA or
IL-6 did not differ among the patients with
a good and a poor outcome during the acute
episode of peritonitis. In patients with a
good primary outcome but a later relapse/
re-infection the concentrations of sICAM-
1 and HA were lower at the end of antibiot-
ic therapy than in patients with a good out-
come and no relapse/re-infection (Figure 4).
Dialysate IL-6 measured two months
after onset of peritonitis was higher than in
a group of patients with no history of peri-
tonitis (Figure 5). sICAM-1 and HA con-
centrations did not differ between these two
groups.
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Part 2. Influence of glucose-free
dialysis solutions on host defence and
on metabolism (IV, V)
Both ID and AA were well tolerated. Nei-
ther episodes of sterile peritonitis nor skin
rash during ID were seen. Some patients
complained of inflow-pain when ID was
started. The total amount of glucose used
in the dialysis solutions (glucose load) de-
creased during both ID (before ID
154.6±4.8 g/day vs. during the use of ID
107.4±4.7g/day, P<0.0001) and AA (before
AA 157.3±6.6 g/day vs. during the use of
AA 125.5±6.7 g/day,  P<0.0001). The glu-
cose load during the use of ID was less
than during the use of AA (P=0.03).  The
mean ultrafiltration rates increased during
the use of ID (from 1250±167 to 1625±195
mL/24 h, P=0.01) but did not change dur-
ing the use of AA (1375±152 vs. 1350±134
mL/24h).
1. Influence of glucose-free solutions
on host defence (IV)
Four patients had an episode of bacterial
peritonitis during the study: two of them
appeared shortly after beginning the use of
ID and the other two shortly after begin-
ning the use of AA. Exclusion of the pa-
tients with peritonitis during the follow-up
did not affect the changes in the levels of
CRP or the soluble factors in the dialysate.
1.1. CRP
Medians of sensitive CRP values were
above normal range in all measurements.
CRP increased during the use of ID (2.3
[0.7-9.0] – 5.0 [0.8-16.0] mg/L, P=0.01),
whereas no significant changes during the
use of AA were seen. CRP values correlat-
ed with BMI in all measurements (r=0.5-
0.6, P=0.009-0.05).
1.2.  Soluble factors in the dialysate
CA125 increased significantly during the use
of AA (22.8 [5.4-89.0] – 42.9 [7.1-92.9]
kU/L, P=0.007).  IL-6 increased significant-
ly during the use of both ID (25.5 [8.0-
82.0] – 40.0 [12.0-118.0] ng/L, P=0.008)
and AA (22.0 [9.0-108.0] – 36.5 [14.0-93.0]
ng/L, P=0.002). TNF-α increased during
the use of ID (1.4 [0.5-2.3] – 1.8 [0.6-7.9]
ng/L, P=0.0008), but no significant chang-
es were seen during the use of AA. sICAM-
1 and HA did not change significantly dur-
ing either study solution. The levels of the
soluble factors measured during the use of
solely glucose-based solutions (i.e. before
ID and before AA) did not show any sig-
nificant differences compared with each
other.
2. Influence of glucose-free solutions
on nutritional state and on
metabolism (V)
2.1. Serum albumin and body mass index
Serum albumin levels showed no signifi-
cant changes during the use of ID or AA
(31.0±0.9 g/L before and after 8 weeks’
use of ID; 29.8±0.9 g/L before AA and
30.3±0.9 g/L after 8 weeks’ use of AA,
P=NS). BMI did not change significantly
during the use of either study solution
(25.1±0.5 kg/m2 before and after 8 weeks’
use of ID; 25.3±0.4 kg/m2 before AA and
25.5±0.4 kg/m2 after 8 weeks’ use of AA,
P=NS).
2.2. Serum lipids
Serum lipids  and FFA are shown in Table
6. Cholesterol declined during the use of
AA (P=0.045), but showed no significant
changes during the use of ID. LDL and HDL
cholesterol did not change significantly dur-
ing the use of either glucose-free solution.
35
Triglycerides decreased during the use of
both ID (P=0.019) and AA (P=0.024).  Free
fatty acids declined during the use of AA
(P=0.022), but showed no significant
changes during ID.
2.3. Values related to glucose metabolism
and insulin sensitivity
Values related to glucose metabolism and in-
sulin sensitivity were analysed separately in
diabetic and non-diabetic patients. The insu-
lin values (at the start of the study) were
higher in the diabetic patients than in the non-
diabetic ones (7.2±0.8 vs. 5.6±0.2 mU/L,
P=0.005). Furthermore, diabetic patients had
higher HbA1c values (7.8±0.3 vs. 6.1±0.2 %,
P=0.0002). The KITT-values (2.6±0.4 vs.
4.4±0.5 %/min, P=0.04) and the QUICKI
values (0.36±0.01 vs. 0.43±0.01, P=0.008)
were lower in the diabetic than in the non-
diabetic patients. The KITT and QUICKI val-
ues correlated closely with each other (r=0.7,
P=0.0005). There were no significant chang-
es in insulin, HbA1c or in insulin sensitivity
measured with the short insulin tolerance test
or with the QUICKI index during the use of
either study solution.
2.4. Substrate oxidation and energy
expenditure
The changes in substrate oxidation during
the use of ID and AA are shown in Tables
7a and 7b. Glucose oxidation decreased
(P=0.013) and lipid oxidation increased
(P=0.017) during eight weeks of using ID,
but showed no significant changes during
the use of AA. RQn decreased during the
use of ID significantly (P=0.012), whereas
no significant changes were seen during
AA. There were no significant changes in
energy expenditure values during the use
of either solution.
Table 6: Serum lipids and FFA before and after the 8 weeks use of ID and AA, respectively
(Study V)
ID (N=20) AA (N=20)
before 8 weeks before 8 weeks
Cholesterol (mmol/L) 5.1±0.3 5.0±0.3 4.8±0.3 4.5±0.3*
    HDL-cholesterol 1.2±0.1 1.2±0.1 1.2±0.1 1.2±0.1
    LDL-cholesterol 2.9±0.2 2.9±0.3 2.8±0.2 2.6±0.3
Triglycerides (mmol/L) 2.2±0.2 1.9±0.1* 1.9±0.2 1.6±0.1*
FFA (µmol/L) 495.0±31.9 534.6±36.0 496.1±34.5 425.8±36.8*
* P<0.05
All values are mean ± SEM.
Table 7a: Substrate oxidation during the use of ID (Study V)
Before ID After 1 week After 8 weeks
GOX (mg/kg/min) 2.20±0.18 1.73±0.14* 1.70±0.13*
LOX (mg/kg/min) 0.38±0.05 0.54±0.06 0.52±0.06*
EE (mg/kg/min) 1.03±0.03 1.03±0.03 1.00±0.03
RQn 0.91±0.01 0.87±0.01* 0.88±0.01*
* P<0.05
All values are mean ± SEM.
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3. Combined use of glucose-free
solutions
Measurements of HBA1c, serum lipids and
substrate oxidation of the eight patients who
used ID and AA simultaneously are shown
in Table 8. There were no significant chang-
es in HbA1c and serum lipids during the com-
Table 7b: Substrate oxidation during the use of AA (Study V)
Before AA After 1 week After 8 weeks
GOX (mg/kg/min) 2.00±0.14 1.91±0.16 2.05±0.15
LOX (mg/kg/min) 0.41±0.05 0.40±0.06 0.33±0.06
EE (mg/kg/min) 1.00±0.03 1.00±0.03 0.98±0.03
RQn 0.90±0.02 0.90±0.02 0.91±0.02
All values are mean ± SEM.
Table 8: Serum lipids, HbA1c, and substrate oxidation during the combined use of ID and AA
compared to the use of ID or AA alone, and to the use of solely glucose-based solutions in
eight patients (Study V)
Glucose 8 weeks ID 8 weeks AA 8 weeks ID+AA
Cholesterol (mmol/L) 4.7±0.5 4.6±0.4 4.4±0.5 4.6±0.5
   HDL-cholesterol 1.2±0.1 1.2±0.1 1.2±0.1 1.2±0.1
   LDL-cholesterol 2.7±0.4 2.7±0.4 2.6±0.5 2.7±0.5
Triglycerids (mmol/L) 1.6±0.3 1.5±0.2 1.5±0.2 1.4±0.1
HbA1c (%) 6.6±0.3 6.5±0.4 6.3±0.4 6.2±0.3
GOX (mg/kg/min) 2.33±0.24 2.01±0.24 2.27±0.17 1.47±0.20*
LOX (mg/kg/min) 0.36±0.07 0.43±0.09 0.25±0.07 0.58±0.09*
EE (mg/kg/min) 1.00±0.06 0.98±0.05 0.94±0.06 0.97±0.06
RQn 0.93±0.02 0.92±0.03 0.93±0.02 0.85±0.02*
P<0.05 (ID+AA compared to glucose, ID or AA)
All values are mean ± SEM.
bined use of ID and AA, compared to ID or
AA used alone, or to the use of solely glu-
cose-based solutions. The decrease in glu-
cose oxidation and the increase in lipid ox-
idation seen during the use of ID alone were
accentuated during the simultaneous use of
ID and AA.
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DISCUSSION
Although PD is undoubtedly an elegant treat-
ment modality of ESRD, the proportion of
patients receiving PD as renal replacement
therapy (RRT) has not increased during the
past years in Finland (Finnish Registry for
Kidney Diseases, Annual Report 2003). The
success of PD has also decreased world
wide: according to the latest report of the
United States Renal Data System, the inci-
dent rates for peritoneal dialysis fell almost
4.5% per year from 1998 to 2002 (USRDS
2005). There are still several unsolved ques-
tions and problems which need a major in-
put of research and exploration: peritonitis
as the major cause of drop-out from PD,
nutritional problems, long-term alterations
in the peritoneal function induced by e.g.
unphysiological dialysis solutions, and fi-
nally, unfavourable metabolic features and
high cardiovascular morbidity and mortali-
ty of the PD patients (Lindholm and Nor-
beck 1986, Young et al. 1991, Davies et al.
1998a, De Vriese et al. 2001a, Gokal 2002,
Piraino et al. 2005).
Part 1. Influence of dialysis adequacy,
characteristics of the peritoneal
membrane and peritonitis on
inflammatory and fibrotic parameters
in the dialysate (I-III)
1. Dialysis adequacy during a one-
year follow-up
It is known that long-term use of PD may
be limited by gradual alterations in perito-
neal function, leading to inadequate solute
removal and ultrafiltration (Heimburger et
al. 1990, Davies et al. 1996, Oreopoulos
and Rao 2001, Davies and Williams 2003,
Smit et al. 2004). Previous studies have
shown that solute transfer increases and
ultrafiltration declines along with time on
peritoneal dialysis (Davies et al. 1996,
Heimburger et al. 1999, Smit et al. 2004).
This process can be exacerbated and accel-
erated by peritonitis (Davies et al. 1996).
However, in the one-year follow-up study
no significant changes in dialysis-related pa-
rameters were found. There are several ex-
planations for this. First, the study group
consisted of a limited number of patients
with a heterogeneous PD duration and sec-
ond, it is highly probable that a longer fol-
low-up period would have allowed more sig-
nificant changes to come up. The fall in re-
sidual renal function was obvious though not
significant. It could be compensated by in-
creasing the delivered PD dose, so that the
total solute removal, i.e. urea Kt/V and cre-
atinine clearances and ultrafiltration would
remain unchanged.  Increasing the PD dose
included increasing the glucose concentra-
tions of the conventional dialysis solutions
or adding icodextrin to the treatment.
2. Nutrition
Based on the declining albumin levels, it can
be assumed that the nutritional status dete-
riorated during one year of follow-up. Nu-
tritional problems are common among PD
patients (Young et al. 1991). They may be
caused by e.g. poor appetite, inadequate
food intake, insufficient dialysis, and pro-
tein loss through the peritoneal membrane.
In the present study, the dialysis efficacy
remained stable, and solute removal fulfilled
the recommendations of DOQI guidelines
(NKF-K/DOQI Clinical Practice Guidelines
2000) Thus, it seems unlikely that inade-
quate dialysis would have caused deterio-
ration of the nutritional status.
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The role of inflammation in connection
with malnutrition has been recognised only
in recent years (Stenvinkel et al. 2000, Pe-
coits-Filho et al. 2002b, Danielski et al. 2003).
High CRP and low albumin values have been
shown to predict poor outcome in PD pa-
tients (Spiegel and Breyer 1994; Cueto-Man-
zano et al. 2001, Wang et al. 2003, Wang et
al. 2004). Association of malnutrition and
inflammation with atherosclerosis (MIA syn-
drome) has brought new knowledge of the
aetiology of cardiovascular diseases (Sten-
vinkel et al. 2000, Pecoits-Filho et al. 2002b).
In the present study, dialysate IL-6 at the
start was associated with a subsequent de-
cline in albumin concentrations. Thus, even
if the soluble factors in the dialysate are
mainly produced locally, dialysate IL-6 seems
to reflect also systemic inflammation, which
may play a role in the decline of albumin con-
centrations, as a marker of deteriorating nu-
tritional status.
3. Characteristics of the peritoneal
membrane
In the most common type of ultrafiltration
failure, the permeability of the peritoneum
for small solutes remains good, but the os-
motic effect of glucose is poor because of
the rapid glucose absorption and dissipa-
tion of the concentration gradient (Oreopou-
los and Rao 2001, Smit et al. 2004).  In the
cross-sectional study plasma loss, which
reflects permeability of the peritoneal mem-
brane, correlated strongly with area param-
eter and the levels of inflammatory factors
in the dialysate. During the one-year fol-
low-up, there were no significant changes
in the characteristics of the peritoneal mem-
brane, but parameters which reflect per-
meability and vascularisation of the perito-
neal membrane such as absorption rate, plas-
ma loss and the area parameter, tended to
increase. These findings are in concordance
with previous reports, assuming that peri-
toneal transport rates and permeability in-
crease with the time on PD (Davies et al.
1996, Heimburger et al. 1999, Smit et al.
2004). Due to increasing CA125 levels dur-
ing the use of ID in the follow-up study, a
preventive effect on the peritoneal mem-
brane can be postulated. This is supported
by previous studies suggesting enhanced
biocompatibility of ID (Barre et al. 1999,
Cooker et al. 1999, Posthuma et al. 2001).
4. Soluble factors in the dialysate
It is known that excretion of cytokines and
growth factors is accelerated during an
acute episode of peritonitis (Brauner et al.
1996, Lai et al. 2000). Simultaneously, the
permeability and vasodilatation in the peri-
toneal membrane increase at least transient-
ly. Also glucose and other bioincompatible
factors of dialysis solutions may irritate the
peritoneal membrane and lead to subclini-
cal inflammation, which may also be medi-
ated by growth factors, cytokines and ad-
hesion molecules. This is supported by the
correlation of plasma loss with area and with
inflammatory  markers of dialysate dem-
onstrated in the cross-sectional study. Fur-
ther, all inflammatory markers (sICAM-1,
HA, TNF-α, IL-6) correlated with each oth-
er; this emphasises the complexity of the
network of cytokines, growth factors and
adhesion molecules in inflammatory proc-
esses.
Based on the findings of stable dialysis
efficacy and characteristics of the perito-
neal membrane, and of the unchanged lev-
els of CA125, it can be postulated that no
serious changes in mesothelial cell mass and
peritoneal function occurred during the one-
year follow-up. This may be one explana-
tion why no significant changes in sICAM-
1 or HA excretion were found, even though
some other investigators have found in-
creasing HA production with the length of
time on CAPD (Yamagata et al. 1999).
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Higher concentrations of IL-6 in the di-
alysate than in serum support local produc-
tion of the soluble factors in the peritone-
um. Increasing IL-6 in the dialysate may
reflect inflammation in the peritoneal mem-
brane, which may lead to alterations in peri-
toneal function with time. However, the role
of IL-6 in inducing inflammation is com-
plex, and IL-6 has also anti-inflammatory
properties (Jones et al. 2001b). Further-
more, the role of soluble IL-6 receptor (sIL-
6R) as a modulator and regulator of the ef-
fects of IL-6 has become more evident in
the past few years (Jones et al. 2001b).
Thus, advanced studies with e.g. combined
measurements of IL-6 and sIL-6R are need-
ed for drawing further conclusions.
5. Peritonitis
Despite technical and medical improve-
ments, peritonitis is still the major compli-
cation of PD,  causing a considerable drop-
out from PD (Piraino et al. 2005). Espe-
cially recurrent and severe episodes of peri-
tonitis damage the peritoneal membrane
(Davies et al. 1996). In the current study,
seven of 36 patients with peritonitis (19.4%)
discontinued PD, and one patient (2.8%)
died. Particularly episodes caused by bac-
teria of enteric origin are problematic
(Tzamaloukas et al. 1993, Kim et al. 2004).
This is supported by findings of the present
study: three of five episodes (60%) caused
by intestinal pathogens had a poor outcome,
whereas none of the patients with an epi-
sode of peritonitis caused by Str. Viridans
discontinued  PD.
Several studies have shown increased
excretion of cytokines and growth factors
during an acute episode of peritonitis (Braun-
er et al. 1996, Lai et al. 2000). Also in the
present study, all measured soluble factors
had the highest concentrations at the onset
of peritonitis. The levels of soluble factors
did not differentiate between patients with
a good or a poor outcome, but high leuko-
cytes and CRP during the acute episode of
peritonitis indicated poor outcome. On the
other hand, low sICAM-1 and HA at the
end of the treatment with antibiotics were
negative prognostic indicators, predicting
the development of a relapse or re-infec-
tion. This may be a sign of reduced host
defence, which may be due to the destruc-
tion of peritoneal cells or reduced immune
capacity. It is also possible that during se-
vere infections, activated leukocytes bind
more ICAM-1, which in turn binds HA, and
the concentrations are therefore lower.
Most previous studies have been con-
fined to the acute phase of peritonitis. In
the present study, the excretion of IL-6 was
accelerated as late as two months after the
onset of peritonitis, pointing to ongoing
inflammation in the peritoneal membrane
also after clinical recovery. Lai et al. (2000)
followed patients 6 weeks after the onset
of peritonitis and reported similar results.
Increased excretion of cytokines, growth
factors and adhesion molecules seems to
be of benefit during the acute episode of
peritonitis. However, sustained excretion
may be a sign of ongoing inflammatory
processes in the peritoneal membrane and
lead to changes in peritoneal function in the
long run.
Part 2. Influence of glucose-free
dialysis solutions on host defence and
on metabolism (IV,V)
Not only peritonitis, but also glucose and
other bioincompatible factors such as low
pH, GDP and hyperosmolality of the con-
ventional dialysis solutions are regarded
as injurious to the peritoneal membrane
(Figure 1) (Liberek et al. 1993a, Witowski
et al. 1995,  De Vriese et al. 2001a, Witowski
et al. 2001a, Mortier et al. 2004a).  Further,
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glucose which is absorbed from the perito-
neal cavity, is considered to contribute to
metabolic disturbances in PD patients (De
Santo et al. 1979, Lindholm and Norbeck
1986, Holmes and Shockley 2000). In the
present study, glucose load could be re-
duced significantly when glucose was re-
placed by ID or AA in one daily exchange.
1. Biocompatibility
Based on the majority of the previous stud-
ies icodextrin and amino-acid-based solu-
tions are considered to be more biocom-
patible than glucose-containing solutions
(Brulez et al. 1996, Garosi et al. 1998, Barre
et al. 1999, Cooker et al. 1999, Bajo et al.
2000, Ha et al. 2002, Chan et al. 2003).
However, some studies have shown equal
cell culture cytotoxicity with ID as with
conventional glucose-based solutions (Lib-
erek et al. 1993b, Plum et al. 1998, Post-
huma et al. 2000). On the other hand, Pa-
rikova et al. found more signs of subclini-
cal inflammation during the use of icodex-
trin than during the use of glucose-based
solutions (Parikova et al. 2003). Further-
more, Gotloib et al. found mesothelial dys-
plastic changes and lipid peroxidation in-
duced by icodextrin  (Gotloib et al. 2002).
Most studies are based on in vitro study
designs with cell cultures. In vivo evidence
is still rare.
A half of the patients in the present study
had elevated CRP values in all four meas-
urements. According to previous reports
analysing the importance of CRP to risk
stratification, elevated CRP levels can be
considered to present enhanced risk for
cardiovascular diseases (Ducloux et al.
2002, Blake et al. 2003, Wang et al. 2004).
Some recent reports assume that low-grade
inflammation is associated with obesity
(Visser et al. 1999, Yudkin 2003). This is
supported by the correlation of BMI and
CRP found in the present study.
Surprisingly, the CRP levels increased
during the use of ID. We are not aware of
any reports of CRP values during the use
of amino acid solution or icodextrin, ex-
cept during episodes of sterile peritonitis
during the use of ID. Although the study
was partly conducted at a time when some
icodextrin batches contained a higher level
of peptidoglycans, no signs or symptoms
of sterile peritonitis were observed during
the study. Thus, it is unlikely that the in-
crease would be related to sterile peritoni-
tis. More research is still needed to clarify
this issue.
Also parameters of local inflammation
increased during the use of glucose-free
solutions, e.g. TNF-α and IL-6 during ID
and IL-6 during AA. This can be interpret-
ed in two ways: as a sign of enhanced ca-
pacity of host defence or as a marker of
irritation and inflammation in the peritone-
um. Based on previous reports indicating
enhanced biocompatibility of ID and AA
(Garosi et al. 1998, Barre et al. 1999, Cooker
et al. 1999, Bajo et al. 2000, Ha et al. 2002,
Chan et al. 2003) and on the increasing
CA125 during AA as a marker of better
mesothelial preservation in the present
study, it is likely that increasing IL-6 and
TNF-α are signs of less cellular inhibition
and better preservation of cytokine release
during the use of glucose-free solutions.
However, inflammatory processes which
may cause alterations in the peritoneal mem-
brane in the long run, cannot totally be ex-
cluded.
2. Nutrition and glucose and lipid
metabolism
Because several classical risk factors of
cardiovascular diseases, such as unfavour-
able lipid profiles, hyperinsulinaemia and
features of insulin resistance, are at least
partly associated with constant glucose load
from the peritoneal cavity (De Santo et al.
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1979, Lindholm and Karlander 1986, Lind-
holm and Norbeck 1986, Holmes and
Shockley 2000) it can be assumed that glu-
cose-free dialysis solutions may have a ben-
efit on glucose and lipid metabolism.
Some studies have shown favourable
changes in insulin sensitivity and serum li-
pids during ID (Amici et al. 2001, Bredie et
al. 2001, Sisca and Maggiore 2002), where-
as the effects of AA on serum lipids have
been controversial (Young et al. 1989, Misra
et al. 1997, Brulez et al. 1999). The find-
ings of the present study support the evi-
dence of beneficial effects of ID and AA on
serum lipids. Hyperlipidaemia with PD has
been attributed to the continuous absorp-
tion of glucose (Lindholm and Norbeck
1986, Holmes and Shockley 2000). It has
been suggested that approximately 60-80%
of the glucose installed into the peritoneal
cavity is absorbed, corresponding to 100-
300g of glucose intake per day (Holmes and
Shockley 2000). In the present study, the
daily glucose load could be reduced by 15-
30% as icodextrin or amino acids were used
as osmotic agents instead of glucose in one
daily exchange. This might explain the fa-
vourable effects of ID and AA on serum
lipids.
Contrary to a previous report (Amici et
al. 2001) we could not show any signifi-
cant differences in insulin sensitivity dur-
ing the use of ID or AA. The short insulin
tolerance test has a coefficient of variation
of 6±2% (Akinmokun et al. 1992); thus,
the use of a more sophisticated method like
the insulin clamp technique (DeFronzo et
al. 1979) could have enabled detecting the
changes in insulin sensitivity more accu-
rately. Furthermore, the eight-week follow-
up periods may have been too short  to
measure changes in insulin sensitivity com-
pletely.
There was no increase in albumin dur-
ing the use of AA. Even if the concept of
offering amino acids through the peritone-
um is attractive, the view that amino acid
solution could improve nutritional status has
not been totally confirmed (Bruno et al.
2000). As discussed below, the reasons for
poor nutrition are manifold. This may be
one explanation for the varying success of
amino acid solutions to improve nutrition
in different studies.
Substrate oxidation changed into a more
physiological condition during the use of
ID and even more during the combined use
of ID and AA. The background for these
effects is probably the reduced glucose load
during the use of glucose-free solutions.
Glucose uptake represents a significant pro-
portion of daily substrate uptake in CAPD
patients (De Santo et al. 1979, Holmes and
Shockley 2000). They show preferential
utilisation of glucose as an energy substrate
and a lower rate of lipid oxidation. Similar
changes are observed in healthy persons
maintained on high dietary carbohydrate
intake (Simonson and DeFronzo 1990). Due
to the Randle cycle, there is a competition
between glucose and fatty acids as oxida-
tive fuel sources (Randle et al. 1963). The
preferential oxidation of glucose as an en-
ergy substrate may represent an adaptive
mechanism to glucose ‘over load’. How-
ever, the ability to metabolise an exogenous
glucose load is dependent on the insulin
sensitivity of the tissues. It is known that
uraemic patients are insulin-resistant  (De-
Fronzo et al. 1981, Lindholm and Karlander
1986). Thus, it can be postulated that re-
ducing the glucose load and the amount of
glucose oxidation leads to a more physio-
logical balance of substrate oxidation in
CAPD patients.
It can be assumed that reduction of the
unfavourable risk profile by using glucose-
free dialysis solutions may lead to reduced
morbidity and mortality from cardiovascu-
lar diseases. However, this must be con-
firmed by larger studies with long follow-
up periods.
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Vision of optimal PD treatment
The vision of optimal PD treatment in the
future aims at enhanced biocompatibility and
at neutral or even beneficial metabolic in-
fluences. The means of achieving this goal
include a combination of several glucose-
free dialysis solutions, using solutions with
neutral osmolality and pH and with low lev-
els of glucose degradation products. New
solutions with both a glucose-free osmotic
agent and a neutral pH will probably be in-
troduced in the near future. As a result of
these developments, future PD treatments
will be safe and effective, and they can be
tailored to the needs of the individual pa-
tient.
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SUMMARY AND CONCLUSIONS
1. The soluble factors measured in the di-
alysate showed no correlation to the pa-
rameters of dialysis efficacy, but corre-
lated strongly with plasma loss, which
may reflect inflammation in the perito-
neum. Further, dialysate IL-6 correlat-
ed with the number of previous episodes
of peritonitis. The soluble factors in the
dialysate could thus be an indicator of
ongoing inflammatory processes, which
may lead to functional failure of the peri-
toneal membrane.
2. There were no changes in the parame-
ters of dialysis efficacy or membrane
characteristics during the one-year fol-
low-up. Increasing IL-6 may reflect in-
flammation in the peritoneal membrane,
which may lead to alterations in the peri-
toneal function in the long run. Icodex-
trin seemed to have a preventive effect
on mesothelial cell mass.
3. High dialysate leukocytes and serum
CRP on day 4 of peritonitis predicted
poor outcome of peritonitis. Low sI-
CAM-1 and HA in the dialysate at the
end of the treatment with antibiotics
were accompanied by a relapse or re-
infection. IL-6 remained higher even two
months after clinical recovery of peri-
tonitis, suggesting ongoing inflamma-
tion, which may limit the longevity of
the peritoneal membrane.
4. The use of glucose-free solutions may
lead to improvement of host defence.
However, an activation of systemic and
peritoneal inflammation during the use
of ID, and, to a lesser extent during AA,
cannot be totally excluded. AA may pre-
serve the peritoneal membrane.
5. The use of glucose-free solutions, i.e.
ID and AA, was beneficial concerning
substrate oxidation and the lipid profile.
Changes in insulin sensitivity could not
be shown. It remains to be seen, wheth-
er larger studies with longer follow-up
periods allow changes in insulin sensi-
tivity to come up.
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